Imugene (ASX:IMU) - CEO, Leslie Chong
CEO, Leslie Chong
Source: Imugene
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) receives notice of grant from the Japanese Patent Office for its HER-Vaxx immunotherapy
  • The patent is titled ‘A vaccine Composition and Uses Thereof’ and protects the method of use and composition of Imugene’s immunotherapy until 2036
  • HER-Vaxx is designed to treat tumours that over-express the HER-2/neu receptor such as gastric, ovarian, lung and breast
  • Roughly 75 per cent of all gastric cancer diagnoses are in Asia with Japan having the third highest incidence rate of gastric cancer worldwide
  • Shares in Imugene are up 5.49 per cent and are trading at 48 cents at 10:45 am AEST

Imugene (IMU) has received notice of grant from the Japanese Patent Office for its HER-Vaxx immunotherapy.

The patent is titled ‘A vaccine Composition and Uses Thereof’ and protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy until 2036.

The HER-Vaxx immunotherapy is designed to treat tumours that over-express the HER-2/neu receptor such as lung, breast, gastric, ovarian and pancreatic cancers.

Roughly 75 per cent of all gastric cancer diagnoses are in Asia with Japan having the third highest incidence rate of gastric cancer worldwide.

CEO and Managing Director Leslie Chong commented on the granting.

“Attaining the key Japanese patent is an important milestone,” Ms Chong said.

“This adds extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in one of the world’s largest HER2 positive gastric cancer markets until 2036.”

Shares in Imugene were up 5.49 per cent and were trading at 48 cents at 10:45 am AEST.

imu by the numbers
More From The Market Online

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…